TY  - GEN
AU  - Garcia-Manero,Guillermo
AU  - Tibes,Raoul
AU  - Kadia,Tapan
AU  - Kantarjian,Hagop
AU  - Arellano,Martha
AU  - Knight,Emily A
AU  - Xiong,Hao
AU  - Qin,Qin
AU  - Munasinghe,Wijith
AU  - Roberts-Rapp,Lisa
AU  - Ansell,Peter
AU  - Albert,Daniel H
AU  - Oliver,Brian
AU  - McKee,Mark D
AU  - Ricker,Justin L
AU  - Khoury,Hanna Jean
TI  - Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies
SN  - 1573-0646
PY  - 2016///0512
KW  - Aged
KW  - Aminopyridines
KW  - adverse effects
KW  - Antineoplastic Agents
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Aurora Kinases
KW  - antagonists & inhibitors
KW  - Azacitidine
KW  - Female
KW  - Hematologic Neoplasms
KW  - drug therapy
KW  - Humans
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Phenylurea Compounds
KW  - Protein Kinase Inhibitors
KW  - Receptors, Vascular Endothelial Growth Factor
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s10637-015-0242-6
ER  -